IGFBP1 in epithelial circulating tumor cells as a potential response marker to selective internal radiation therapy in hepatocellular carcinoma

Biomarkers in Medicine

Volumn 8, Issue 5, 2014, Pages 687-698

  Nel, Ivonne ^a   Baba, Hideo A ^a   Weber, Frank ^a   Sitek, Barbara ^b   Eisenacher, Martin ^b   Meyer, Helmut E ^b   Schlaak, Joerg F ^a,c   Hoffmann, Andreas Claudius ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Department of General Visceral and Transplantation Surgery University Hospital of Essen ^*  (Germany)

Author keywords

AFP; circulating tumor cells; EpCAM; epithelial cells; hepatocellular carcinoma; IGFBP1; peripheral blood; SIRT

Indexed keywords

MESSENGER RNA; SOMATOMEDIN BINDING PROTEIN 1; CELL ADHESION MOLECULE; TRANSCRIPTOME; TUMOR ANTIGEN; TUMOR MARKER; TUMOR-ASSOCIATED ANTIGEN GA733;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CELL ISOLATION; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; EPITHELIAL CIRCULATING TUMOR CELL; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IGFBP1 GENE; LIVER CELL CARCINOMA; MALE; MARKER GENE; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; QUANTITATIVE ANALYSIS; RADIATION RESPONSE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SELECTIVE INTERNAL RADIATION THERAPY; TUMOR VOLUME; ADOLESCENT; BLOOD; CARCINOMA, HEPATOCELLULAR; DISEASE COURSE; EPITHELIUM CELL; GENETICS; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; TUMOR EMBOLISM; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES; DISEASE PROGRESSION; EPITHELIAL CELLS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; TRANSCRIPTOME; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84906260704     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.14.23     Document Type: Article

References (28)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 362 (9399), 1907-1917 (2003).
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011).
3. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N. Engl. J. Med. 352(25), 2589-2597 (2005).
4. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355(10), 983-991 (2006).
5. Sangro B, Bilbao JI, Boan J et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 66(3), 792-800 (2006).
6. Lau WY, Lai EC, Leung TW. Current role of selective internal irradiation with yttrium-90 microspheres in the management of hepatocellular carcinoma: a systematic review. Int. J. Radiat. Oncol. Biol. Phys. 81(2), 460-467 (2011).
7. Sun YF, Yang XR, Zhou J, Qiu SJ, Fan J, Xu Y Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. J. Cancer Res. Clin. Oncol. 137(8), 1151-1173 (2011).
8. Allard WJ, Matera J, Miller MC et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 10(20), 6897-6904 (2004).
9. Moldenhauer G, Momburg F, Moller P, Schwartz R, Hammerling GJ. Epithelium-specifc surface glycoprotein of Mr 34, 000 is a widely distributed human carcinoma marker. Br. J. Cancer 56(6), 714-721 (1987).
10. Zhang N, Li X, Wu CW et al. microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis. Oncogene 32(42), 5078-5088 (2012).
11. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351(8), 781-791 (2004).
12. Gauler TC, Theegarten D, Parr A et al. Decrease of circulating tumor cells associates with response to platinum-based chemotherapy in patients with non-small cell lung cancer, but not with small cell lung cancer. J. Thorac. Oncol. 6(6), S1114-S1114 (2011).
13. Waguri N, Suda T, Nomoto M et al. Sensitive and specifc detection of circulating cancer cells in patients with hepatocellular carcinoma; detection of human telomerase reverse transcriptase messenger RNA after immunomagnetic separation. Clin. Cancer Res. 9(8), 3004-3011 (2003).
14. Xu W, Cao L, Chen L et al. Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy. Clin. Cancer Res. 17(11), 3783-3793 (2011).
15. Vona G, Estepa L, Beroud C et al. Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. Hepatology 39(3), 792-797 (2004).
16. Guo J, Yao F, Lou Y et al. Detecting carcinoma cells in peripheral blood of patients with hepatocellular carcinoma by immunomagnetic beads and RT-PCR. J. Clin. Gastroenterol. 41(8), 783-788 (2007).
17. Schulze K, Beneken C, Staufer K et al. Detection of Epcam-positive circulating tumor cells in patients with hepatocellular carcinoma-a pilot study. Hepatology 54, 1357a-1357a (2011).
18. Nel I, Baba HA, Ertle J et al. Individual profling of circulating tumor cell composition and therapeutic outcome in patients with hepatocellular carcinoma. Transl. Oncol. 6(4), 420-428 (2013).
19. Simon F, Bockhorn M, Praha C et al. Deregulation of HIF1-alpha and hypoxia-regulated pathways in hepatocellular carcinoma and corresponding non-malignant liver tissue-infuence of a modulated host stroma on the prognosis of HCC. Langenbecks Arch. Surg. 395(4), 395-405 (2010).
20. Sobin LH. TNM: evolution and relation to other prognostic factors. Semin. Surg. Oncol. 21(1), 3-7 (2003).
21. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92(3), 205-216 (2000).
22. Hoffmann AC, Danenberg KD, Taubert H, Danenberg PV, Wuerl P. A three-gene signature for outcome in soft tissue sarcoma. Clin. Cancer Res. 15(16), 5191-5198 (2009).
23. Hoffmann A-C, Vallboehmer D, Grimminger P et al. Preoperative survivin mRNA detection in peripheral blood is an independent predictor of outcome in esophageal carcinoma. Pharmacogenomics 11(3), 341-347 (2010).
24. Hoffmann A-C, Wild P, Leicht C et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 12(8), 628-636 (2010).
25. Henrich CJ, Budhu A, Yu Z et al. High-throughput screening for identifcation of inhibitors of EpCAM-dependent growth of hepatocellular carcinoma cells. Chem. Biol. Drug Design 82(2), 131-139 (2013).
26. Sun YF, Xu Y, Yang XR et al. Circulating stem celllike EpCAM( +) tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology 57(4), 1458-1468 (2012).
27. Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J. Gastroenterol. 12(8), 1175-1181 (2006).
28. Gong Y, Cui L, Minuk GY. The expression of insulin-like growth factor binding proteins in human hepatocellular carcinoma. Mol. Cell. Biochem. 207(1-2), 101-104 (2000).